CS
Candriam SCA Portfolio holdings
AUM
$17.3B
This Quarter Return
+9.84%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$15.7B
AUM Growth
+$15.7B
(+6.5%)
Cap. Flow
-$63.5M
Cap. Flow
% of AUM
-0.41%
Top 10 Holdings %
Top 10 Hldgs %
22.96%
Holding
929
New
41
Increased
265
Reduced
360
Closed
129
Top Buys
| 1 |
Eli Lilly
LLY
|
$106M |
| 2 |
PayPal
PYPL
|
$58.2M |
| 3 |
Hologic
HOLX
|
$46.2M |
| 4 |
Thermo Fisher Scientific
TMO
|
$36.7M |
| 5 |
Intuitive Surgical
ISRG
|
$34.3M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$79.5M |
| 2 |
Merck
MRK
|
$77.4M |
| 3 |
Apple
AAPL
|
$62.7M |
| 4 |
Verizon
VZ
|
$37.8M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$36M |
Sector Composition
| 1 | Healthcare | 31.3% |
| 2 | Technology | 26.69% |
| 3 | Financials | 8.86% |
| 4 | Communication Services | 7.82% |
| 5 | Consumer Discretionary | 7.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Relay Therapeutics
RLAY
$619M
| $16.3M | 0.1% |
529,885
-33,053
| -6% | -$1.02M |
|
202
Southern Copper
SCCO
$78B
| $16.1M | 0.1% |
261,000
-24,900
| -9% | -$1.54M |
|
203
Cogent Biosciences
COGT
$1.69B
| $16M | 0.1% |
1,865,772
-61,477
| -3% | -$527K |
|
204
UDR
UDR
$13.1B
| $16M | 0.1% |
+266,730
| New | +$16M |
|
205
Becton Dickinson
BDX
$55.3B
| $16M | 0.1% |
63,560
-555
| -0.9% | -$140K |
|
206
CEVA Inc
CEVA
$531M
| $15.8M | 0.1% |
366,080
+6,411
| +2% | +$277K |
|
207
Newmont
NEM
$81.7B
| $15.6M | 0.1% |
251,313
-4,487
| -2% | -$278K |
|
|
ATH
208
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $15.5M | 0.1% |
186,230
-32,830
| -15% | -$2.73M |
|
209
Celldex Therapeutics
CLDX
$1.47B
| $15M | 0.1% |
387,221
+206,999
| +115% | +$8M |
|
210
Guardant Health
GH
$8.41B
| $14.7M | 0.09% |
147,289
+22,917
| +18% | +$2.29M |
|
211
Zebra Technologies
ZBRA
$16.1B
| $14.7M | 0.09% |
24,715
+2,187
| +10% | +$1.3M |
|
212
Travelers Companies
TRV
$61.1B
| $14.7M | 0.09% |
93,853
+69,997
| +293% | +$11M |
|
213
Bank of Montreal
BMO
$86.7B
| $14.7M | 0.09% |
136,170
-51,556
| -27% | -$5.56M |
|
214
Fate Therapeutics
FATE
$120M
| $14.7M | 0.09% |
250,737
| – | – |
|
215
Ecolab
ECL
$78.6B
| $14.7M | 0.09% |
62,506
+1,545
| +3% | +$362K |
|
216
DexCom
DXCM
$29.5B
| $14.6M | 0.09% |
27,244
+21,936
| +413% | +$11.8M |
|
217
DuPont de Nemours
DD
$32.2B
| $14.4M | 0.09% |
178,489
-27,138
| -13% | -$2.19M |
|
218
Keros Therapeutics
KROS
$618M
| $14.1M | 0.09% |
240,946
| – | – |
|
219
Replimune Group
REPL
$422M
| $14.1M | 0.09% |
519,512
-2,629
| -0.5% | -$71.2K |
|
220
Pacira BioSciences
PCRX
$1.2B
| $13.8M | 0.09% |
230,081
+25,121
| +12% | +$1.51M |
|
221
Etsy
ETSY
$5.25B
| $13.6M | 0.09% |
62,097
+11,983
| +24% | +$2.62M |
|
|
222
Verizon
VZ
$186B
| $13.4M | 0.09% |
257,602
-727,174
| -74% | -$37.8M |
|
|
GWB
223
DELISTED
Great Western Bancorp, Inc.
GWB
| $13.3M | 0.09% |
392,323
+118,683
| +43% | +$4.03M |
|
224
Wells Fargo
WFC
$263B
| $13.1M | 0.08% |
273,166
-32,893
| -11% | -$1.58M |
|
225
Cigna
CI
$80.3B
| $13.1M | 0.08% |
56,841
+20,721
| +57% | +$4.76M |
|